Aarti Drugs sees earlier Rs 1,000 crore formulations goal

Aarti Drugs Limited expects to achieve its Rs 1,000 crore formulations-revenue aspiration earlier than previously published, supported by a brownfield expansion expected to double capacity by the middle of next year and an initial US oncology launch. Management said the formulations business had been operating at almost full capacity before the expansion.

Why does Aarti Drugs expect to reach Rs 1,000 crore earlier?

Aarti Drugs expects to reach Rs 1,000 crore earlier because it is expanding capacity, commercialising products in new export markets and increasing utilisation of its oncology facility. Management did not provide a revised year for the aspiration, so the earlier timing is not formal financial guidance. Its stated capacity constraint is important because formulations plants were almost running at full scale.

Export commercialisation drove formulations growth in the reported quarter, management said. Products that had been registered in regulated and emerging markets started reaching newer territories, lifting both revenue and earnings before interest, tax, depreciation and amortisation, or EBITDA, margin. Management called the quarter exceptional but said a similar revenue level could be sustained as more markets and products contribute.

Aarti Drugs had pending formulation export orders covering roughly four months, or more than one quarter. That order visibility supports near-term production, but management did not disclose the value of those orders. It said the export momentum could continue because the company has entered multiple markets with multiple products, while also noting that margins depend on new orders continuing.

How will the brownfield expansion affect Aarti Drugs formulations capacity?

Aarti Drugs said its brownfield expansion should double formulations capacity by the middle of next year. Management directly linked the project to its ability to reach the Rs 1,000 crore revenue landmark earlier, after stating that current capacity was almost fully utilised. The call did not provide current capacity, project cost or a specific commissioning date.

The capacity programme accompanies planned investment in formulation research and development, or R&D. Management said it plans to invest heavily in formulation R&D and reported operating cash flow of roughly Rs 90 crore in the first half across the standalone and formulation businesses, split more or less equally. It did not quantify capital expenditure for formulation R&D or the brownfield expansion.

Aarti Drugs also outlined separate regulatory-market projects in its standalone business. It plans three additional lines in a multipurpose United States Food and Drug Administration, or USFDA, block, which management said could have full-scale revenue potential of Rs 180 crore to Rs 200 crore. It is also expanding metformin capacity and making it USFDA compliant, but those projects are separate from the formulations capacity doubling.

What is Aarti Drugs' current US oncology contribution?

Aarti Drugs said US oncology made only a very small contribution in the reported quarter because its first product was launched recently. Management expects revenue from that one marketed product to increase over the coming three to six months. The US business has therefore begun, but management said it has yet to reach a significant scale.

A second abbreviated new drug application, or ANDA, is due for approval in the next few months, according to management. Approval remains pending, rather than completed. Aarti Drugs also plans to file another four to five oncology products over the rolling 12 months, which would expand the US and regulated-market launch pipeline if filings and approvals progress.

The oncology portfolio comprises about 25 to 30 molecules at different development and sizing stages. Management said many of these products use active pharmaceutical ingredients, or APIs, manufactured by group companies, and described the portfolio as nib and cyclic families of oral-solid oncology products. It did not disclose molecule-level revenue, launch dates or customer names.

How could oncology change Aarti Drugs' formulations mix?

Aarti Drugs said oncology should have slightly higher gross margins than the wider formulations business. Its oncology facility currently has only one or two commercialised products, so management sees higher utilisation as a key part of the Rs 1,000 crore aspiration. The margin comment relates to gross margin, not a disclosed oncology EBITDA margin.

Management estimated that oncology could account for a late-30s to early-40s percentage of revenue by FY30. This is a management estimate, not current revenue contribution, and depends on products advancing from development and filing stages into commercial launches. The company is pursuing its own filings in some countries and a business-to-business model with leading market participants in others.

The stated market strategy spans the US, European Union, United Kingdom, Latin America, the Middle East and Asian markets. Aarti Drugs did not give sales by region, product or customer. The broad geography is intended to support commercialisation across regulated markets, while the existing export business has already been the main contributor to the reported quarter's formulation growth.

Are Aarti Drugs' formulation margins likely to stay at 28%?

Aarti Drugs reported formulation EBITDA margin of roughly 28% in the quarter, which management attributed to favourable export orders. Management did not present 28% as a permanent level. It said that if export orders keep coming, formulation EBITDA margin could be sustained at least in the early 20s.

The difference between the reported 28% and the early-20s indication matters for the consolidated outlook. Management said formulations may represent roughly 15% to 16% of consolidated revenue going forward, while the standalone business may account for about 84% to 85%. It used an illustrative assumption of about 20% formulation EBITDA margin and 14% standalone EBITDA margin to support its view that consolidated margin could remain slightly above 15%.

Consolidated EBITDA margin was about 16.6% in the reported quarter, compared with management's view that around 15% should be sustainable. Management attributed the higher quarterly outcome partly to export-led formulation profitability. It also said standalone margin gains reflected operational and energy optimisation, while formulation gains were mainly driven by gross contribution.

What needs to happen for Aarti Drugs to meet the aspiration sooner?

Aarti Drugs needs to complete the brownfield expansion by the middle of next year, increase sales from its first US oncology product and progress the second ANDA towards approval. It also needs to turn four to five planned oncology filings over the next 12 months into commercial products. Management did not quantify the revenue contribution expected from each milestone.

Export order replenishment is another factor. The company has roughly four months of pending formulation export orders, but management said maintaining early-20s formulation EBITDA margins depends on continued order inflows. The oncology facility also needs utilisation to rise from its current base of one or two commercialised products for the longer-term revenue mix estimate to take shape.

Conclusion

Aarti Drugs' expectation of reaching Rs 1,000 crore in formulations revenue earlier rests on a connected plan: remove a near-full-capacity constraint through a brownfield expansion, build on export-led sales in new markets and scale a newly launched US oncology product. The reported 28% formulation EBITDA margin shows the effect of the current export mix, while management's early-20s margin indication is the more measured operating benchmark.

The next disclosures to watch are progress toward the brownfield expansion's targeted completion by the middle of next year, the expected approval timing for the second US ANDA in the next few months and filings of four to five oncology products over the rolling 12 months. Management's FY30 estimate of oncology contributing a late-30s to early-40s percentage of revenue will also depend on the facility moving beyond its current one or two commercialised products.